Recent

% | $
Quotes you view appear here for quick access.

International Business Machines Corporation Message Board

garysnoop1 217 posts  |  Last Activity: Aug 30, 2015 11:30 AM Member since: Oct 16, 2003
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • garysnoop1 garysnoop1 Aug 30, 2015 11:30 AM Flag

    Go to settings in the new start menue,there you can pick windows 7 start menu classic,toggle it,I'm out of her e,no more on this ,enjoy it ,I do.

    Sentiment: Strong Buy

  • I just did and it has some really good features that were in 7 ex. start menus is the old style w/uprades.and a lot more..I wouldn't post if I didn't think you all would like it..Let me know what you think..

    Sentiment: Strong Buy

  • Reply to

    WINDOWS 10 stinks..

    by whatsinanameanything Aug 29, 2015 9:56 AM
    garysnoop1 garysnoop1 Aug 30, 2015 10:40 AM Flag

    That's for shure!

  • Reply to

    WINDOWS 10 stinks..

    by whatsinanameanything Aug 29, 2015 9:56 AM
    garysnoop1 garysnoop1 Aug 29, 2015 3:25 PM Flag

    sharpness is gone. Slight blurr to all letters and numbers..

  • Reply to

    Inovio and Korean company GeneOne

    by garysnoop1 Aug 28, 2015 2:52 PM
    garysnoop1 garysnoop1 Aug 28, 2015 3:15 PM Flag

    Its a read ive been waiting for,as you..

    Sentiment: Strong Buy

  • Things are starting to happen..

    Sentiment: Strong Buy

  • Shares


    The first vaccine candidate against Middle East respiratory syndrome (MERS) protects mice, camels and monkeys from the disease, paving the way for human trials later this year.

    The so-called DNA vaccine has been developed in a collaboration led by the University of Pennsylvania, United States, and a paper on its success was published today in Science Translational Medicine.*

    Conventional vaccines against viral diseases involve injecting a live virus or a foreign protein, called an antigen, both of which generate a protective immune response in the body.

    The new vaccine instead works by injecting a DNA sequence that codes for a MERS antigen and relying on the patient’s body to make this protein. Lastly, the immune system reacts to the antigens by developing antibodies that defend against future infection.

    Karuppiah Muthumani, a researcher at the University of Pennsylvania and one of the study’s two lead authors, says the DNA vaccine would be safer than conventional vaccines.

    “Unlike attenuated vaccines, which are essentially weakened live viruses, there is no possibility through mutation for reversion into a live replicative virus,” says Muthumani.


    “We have ways to take care of people and help them to recover more quickly but we don’t have specific vaccines and medicines, as yet.”

    Rana Sidani, WHO
    Just one single dose of vaccination protected eight rhesus monkeys used in the study from the MERS virus, the paper states. The same response was seen in three camels that were treated with the DNA vaccine.

    According to David Weiner, another study author, who works with Muthumani at the University of Pennsylvania, two firms are preparing clinical trials. US business Inovio and Korean company GeneOne Life Science are scheduled to take the vaccine “into human safety and efficiency studies by the end of 2015”, he says.

    MERS is prevalent across the Middle East and parts of Asia. The researchers say DNA vaccines are easier to create and use in developing countries than attenuated vaccines, as they need no refrigeration and do not need advanced laboratories for the production of antigens.

    MERS was discovered in 2012 in Saudi Arabia. It causes fever, coughing and dangerous shortness of breath, which kills more than 30 per cent of those it infects. Since its first outbreak, MERS has claimed nearly 500 lives.

    Sentiment: Buy

  • garysnoop1 garysnoop1 Aug 25, 2015 11:39 AM Flag

    Seems to be ramping up..slow and steady..no bad news..

  • Could they be more obvious..

  • ORCROSS, Ga.--(BUSINESS WIRE)--Guided Therapeutics, Inc. (OTCQB: GTHP) announced today that access to the LuViva® Advanced Cervical Scan has been expanded to Costa Rica, bringing to 20 the number of countries where the Company has shipped its non-invasive, point-of-care cervical cancer detection technology.

    “We will continue to focus on new markets, like Costa Rica and others, where LuViva will be used as a front line screener for cervical cancer.”

    “We are pleased to see our growing traction among doctors, governments and distributors in the developing world as stakeholders increasingly recognize that LuViva can help prevent women’s cervical cancer through earlier detection,” said Gene Cartwright, CEO of Guided Therapeutics. “We will continue to focus on new markets, like Costa Rica and others, where LuViva will be used as a front line screener for cervical cancer.”

    World-wide, the market for cervical cancer screening and diagnostics, as currently practiced using cytology (Pap test) for primary screening, is estimated at $6 billion and is projected to grow to almost $9 billion by 2020. Worldwide there are about 2.6 billion women aged 15 years and older who are at risk of developing cervical cancer.

    In Costa Rica, a pilot program using LuViva for screening is set to begin in the coming weeks. Costa Rica has a population of over 1.8 million women ages 15 years and older who are at risk of developing cervical cancer. Current estimates indicate that every year 297 women are diagnosed with cervical cancer and 116 die from the disease. Cervical cancer ranks as the 3rd most frequent cancer among women between 15 and 44 years of age in Costa Rica.

    About LuViva® Advanced Cervical

    Sentiment: Strong Buy

  • Reply to

    UP Date ..Mers..

    by garysnoop1 Aug 25, 2015 9:29 AM
    garysnoop1 garysnoop1 Aug 25, 2015 10:51 AM Flag

    JRA..LOCO..This used to be a honorable institution, but I can't remember when it was..if it was..

    Sentiment: Buy

  • Reply to

    UP Date ..Mers..

    by garysnoop1 Aug 25, 2015 9:29 AM
    garysnoop1 garysnoop1 Aug 25, 2015 9:41 AM Flag

    On the potential of this alone,we should be 10.00 plus.

  • garysnoop1 by garysnoop1 Aug 25, 2015 9:29 AM Flag

    Inovio Pharmaceuticals (INO) recently declared its DNA vaccine targeting the virulent Middle East Respiratory Syndrome (MERS) induced 100% protection from a live virus challenge in a preclinical study. This medical advancement is notable because there is no vaccine or effective treatment for the MERS virus, which is clearly able to transmit from human to human. Since 2012, MERS has infected 1,400 people and killed over 500. Recently, the largest outbreak outside of Saudi Arabia of this emergent global health concern infected 186 people with 36 fatalities in South Korea.

    In preclinical studies, Inovio and its collaborators evaluated its synthetic DNA-based MERS vaccine in mice, camels and monkeys, or non-human primates. In all three species, the vaccine induced robust immune responses capable of preventing the virus from infecting cells. The data from camels is an important finding because camels represent not only a host reservoir of the disease but act as a mode of transmission to humans. In monkeys, all vaccinated animals in the study were protected from symptoms of MERS disease when challenged with a live MERS virus. Inovio has stated on the preventive power of its synthetic DNA-based vaccines in a variety of infectious diseases counting HIV, influenza, hepatitis B, Ebola and dengue.

    Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. The company’s SynCon immunotherapy design has the ability to break the immune system’s tolerance of cancerous cells; and SynCon product design is also intended to facilitate cross-strain protection against known, in addition to new unmatched strains of pathogens, such as influenza.

    Sentiment: Strong Buy

  • garysnoop1 garysnoop1 Aug 20, 2015 2:53 PM Flag

    And we go down .45 proving they can rob us at will.

  • Reply to

    If we announced a complete

    by stillinshock Aug 20, 2015 2:37 PM
    garysnoop1 garysnoop1 Aug 20, 2015 2:50 PM Flag

    You said it..beond manipulation..

  • Frontline Matters in Notice- Inovio Pharmaceuticals, Inc. (NASDAQ:INO), Frontline Matters in Notice- Inovio Pharmaceuticals, Inc. (NASDAQ:INO),
    Posted by: Devon Leftovich 50 mins ago

    Share !
    inShare0Inovio Pharmaceuticals, Inc. (NASDAQ:INO) hit high price of $7.85 to close at $7.64 by are surging 2.69% with session volume was recorded 2.37 Million. Inovio Pharmaceuticals (INO) reported that its DNA vaccine targeting the virulent Middle East Respiratory Syndrome (MERS) persuaded 100% protection from a live virus confront in a preclinical study. This medical advancement is distinguished for the reason that there is no vaccine or effective treatment for the MERS virus, which is clearly able to transmit from human to human. Since 2012, MERS has infected 1,400 people and killed over 500. Recently, the leading outbreak outside of Saudi Arabia of this emergent global health concern infected 186 people with 36 fatalities in South Korea. In preclinical studies, Inovio and its collaborators evaluated its synthetic DNA-based MERS vaccine in mice, camels and monkeys, or non-human primates. In all three species, the vaccine induced robust immune responses capable of preventing the virus from infecting cells. As concerns of stock price volatility, it was 7.04% for a week and 6.10% for a month

    Share !
    inShare0Inovio Pharmaceuticals, Inc. (NASDAQ:INO) hit high price of $7.85 to close at $7.64 by are surging 2.69% with session volume was recorded 2.37 Million. Inovio Pharmaceuticals (INO) reported that its DNA vaccine targeting the virulent Middle East Respiratory Syndrome (MERS) persuaded 100% protection from a live virus confront in a preclinical study. This medical advancement is distinguished for the reason that there is no vaccine or effective treatment for the MERS virus, which is clearly able to transmit from human to human. Since 2012, MERS has infected 1,400 people and killed over 500. Recently, the leading outbreak outside of Saudi Arabia of this emergent global health concern infected 186 people with 36 fatalities in South Korea. In preclinical studies, Inovio and its collaborators evaluated its synthetic DNA-based MERS vaccine in mice, camels and monkeys, or non-human primates. In all three species, the vaccine induced robust immune responses capable of preventing the virus from infecting cells. As concerns of stock price volatility, it was 7.04% for a week and 6.10% for a month

  • Reply to

    All you mouse brains..Here is THE ANIMAL RULE

    by garysnoop1 Aug 19, 2015 2:50 PM
    garysnoop1 garysnoop1 Aug 19, 2015 3:54 PM Flag

    I try!

  • Bash all you want. Everything is down and WE are up..Your #$%$ doesn't work when facts prevail..

  • Reply to

    All you mouse brains..Here is THE ANIMAL RULE

    by garysnoop1 Aug 19, 2015 2:50 PM
    garysnoop1 garysnoop1 Aug 19, 2015 3:37 PM Flag

    again read it you mousers,read it a few times!!

  • Reply to

    All you mouse brains..Here is THE ANIMAL RULE

    by garysnoop1 Aug 19, 2015 2:50 PM
    garysnoop1 garysnoop1 Aug 19, 2015 3:27 PM Flag

    I don't know ,it seemed pretty well layed out to me.bam...we'll see.

IBM
147.5923-0.3877(-0.26%)3:24 PMEDT